about
MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activityCytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic deathThe next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy responseThe NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells.Antitumor potential of conjugable valinomycins bearing hydroxyl sites: in vitro studies.Interaction of the sigma(2) receptor ligand PB28 with the human nucleosome: computational and experimental probes of interaction with the H2A/H2B dimer.Cyclohexylpiperazine derivative PB28, a sigma2 agonist and sigma1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer.Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutationAurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer.Natural history of malignant bone disease in gastric cancer: final results of a multicenter bone metastasis survey.Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy.Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.Phosphatidylinositol 3-kinase in breast cancer: where from here?Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer.Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinomaCarcinogenesis of pancreatic adenocarcinoma: precursor lesions.Intracellular trafficking of MDR transporters and relevance of SNPs.Update on capecitabine alone and in combination regimens in colorectal cancer patients.EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.Anti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidenceThe clinical development of inhibitors of poly(ADP-ribose) polymerase.The impact of folate status on the efficacy of colorectal cancer treatment.Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines.Synthetic lethality to overcome cancer drug resistance.Target therapies in pancreatic carcinoma.New vascular disrupting agents in upper gastrointestinal malignancies.Predictive factors to targeted treatment in gastrointestinal carcinomas.Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers.New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations.Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?The EGFR pathway regulates BCRP expression in NSCLC cells: role of erlotinib.Trimethoxybenzanilide-based P-glycoprotein modulators: an interesting case of lipophilicity tuning by intramolecular hydrogen bonding.Irradiation-induced angiosarcoma and anti-angiogenic therapy: a therapeutic hope?Sigma-2 receptor agonists as possible antitumor agents in resistant tumors: hints for collateral sensitivity.The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line.MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents.Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study.4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators.
P50
Q26799779-05C9FC68-A60D-4D33-BEDF-A28F8939B3AEQ27675558-5AC2CBD6-BFF6-4282-9FFB-CB995BD25B92Q28581047-5C549647-05F0-40AA-9E20-C34C4EDEB15FQ30384301-633AD229-0F18-4345-8F3E-FE7E36B74376Q30479321-3B1E2816-E5C3-4831-BF53-CBE7D83DBAA8Q33635982-9C582762-9257-4D78-8BAB-4333EE38BB1BQ34093031-4B23DFE3-9D0A-45D7-BF39-483855BAE41EQ34554688-B121C843-CD89-433C-A996-354D6351A481Q34599527-646CCBC1-7CC3-4F9B-98CD-D20D5C42A8DBQ34621867-452A7824-ED53-424B-BF52-6F2F0AB048FBQ35034474-D2668683-5005-4B6C-A034-BB97EA9987AEQ35041273-C3563912-ADAF-4D72-98E8-3DEE27A2AE59Q36695154-B67DB372-D3C1-4D2C-ABE0-63AC9FF42D85Q36975572-5903CA8C-E74C-4B37-803D-D2A3E528B185Q37096730-FB05A5C7-C7B3-42D3-8746-3D05CF682086Q37142991-D7094AEC-9043-4BD7-8972-517CCE8F7A0FQ37291172-29826DA0-FEE9-494A-84B7-C336791720F8Q37387620-C3AD7D26-3079-4392-B124-A117F49C68ECQ37815612-7658CCA1-A056-47BD-85E0-4B8FDF57A5A1Q37825245-9350347E-3D2F-4C51-A80D-0860F85B7861Q37825246-C23F4BCA-069A-4196-AAC6-100123E05AE3Q37834139-88B957F0-CBCB-4D94-9A98-C86526453280Q37905070-52BF062E-A767-471B-A994-CC073B121856Q37996443-ACA31F51-91D6-4D0A-B086-D8CC20400E8FQ38025705-D40E336B-CC0B-4B83-9393-14E4F947802FQ38132867-C36B818A-3FC8-491C-B78E-A6BEF49C5F45Q38132873-2EFAF908-A74A-4A81-A00C-022C86E31700Q38216173-D9828367-D908-4B5F-AF9A-A2F8351D08CBQ38699989-D2612B12-A7EF-46D7-995D-1E7C50386075Q38750988-76694844-0115-4BBB-99B9-1DC6D4836A25Q38864606-3E9D9C8C-1F08-4AA7-A0C7-4FEE364F50D2Q38931907-FA953E72-22C1-450E-8236-981672772E34Q38968562-387C1025-F6E7-4D17-BB2B-0A6A22ABC4F2Q39037838-F9922D39-3CFD-403E-95CF-F9673A13279EQ39084283-9B2E107D-D7C3-4643-9F15-43698EFE6449Q39147858-B3D71E53-3F18-4328-AF18-38D0A9A97818Q39472468-11743EEE-1F2F-4CC6-B2B2-CCBE93A6D072Q39631666-5A14CC54-DA0E-49AC-A51D-020399F19E05Q39655391-AD125657-F308-44D6-8B66-D31873A4EB45Q40012957-441F66E9-5639-4298-B241-F06239907C86
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Amalia Azzariti
@ast
Amalia Azzariti
@en
Amalia Azzariti
@es
Amalia Azzariti
@nl
type
label
Amalia Azzariti
@ast
Amalia Azzariti
@en
Amalia Azzariti
@es
Amalia Azzariti
@nl
prefLabel
Amalia Azzariti
@ast
Amalia Azzariti
@en
Amalia Azzariti
@es
Amalia Azzariti
@nl
P106
P1153
6602329030
P21
P31
P496
0000-0002-6149-5049